Glaucoma: Evidence-Based Role of Cannabis and Citrus Compounds in Intraocular Pressure Regulation

Glaucoma is a group of optic neuropathies characterized by progressive retinal ganglion cell loss and visual field deterioration, often associated with elevated intraocular pressure (IOP) but not limited to IOP. Mechanistically, glaucoma reflects a convergence of impaired aqueous humor dynamics, vulnerability of the optic nerve head to stressors, microvascular dysregulation, neuroinflammation, and excitotoxic pathways. The clinical course is typically chronic, frequently asymptomatic early, and may ultimately lead to irreversible blindness without timely treatment.

The most common forms include primary open-angle glaucoma (POAG), angle-closure glaucoma, and secondary glaucomas. In POAG, the trabecular meshwork and downstream aqueous outflow pathways become less effective, leading to higher IOP. In angle-closure glaucoma, iris-lens anatomy narrows the anterior chamber angle and obstructs aqueous outflow, causing acute IOP spikes. Regardless of type, the unifying endpoint is optic nerve damage. Standard diagnosis integrates optic nerve head assessment, retinal nerve fiber layer imaging (e.g., OCT), visual field testing, gonioscopy for angle assessment, and measurement of IOP.

Treatment aims to lower IOP because the strongest evidence for slowing progression links IOP reduction to decreased risk of visual field loss. First-line therapies typically include topical prostaglandin analogs, which enhance uveoscleral outflow; beta-adrenergic blockers that reduce aqueous production; alpha-agonists that reduce production and increase outflow; and carbonic anhydrase inhibitors that decrease aqueous humor generation. In refractory cases or when rapid control is required, laser procedures (e.g., trabeculoplasty) or surgery (e.g., trabeculectomy, tube shunt) are considered. Target IOP is individualized based on baseline severity, risk factors, and rate of progression.

Cannabinoids (e.g., delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) have been studied for potential IOP-lowering effects. Proposed mechanisms include reduction of aqueous humor production and modulation of ocular blood flow via cannabinoid receptor pathways (CB1/CB2) and downstream signaling. However, the evidence base is limited by variability in formulations, dosing, route of administration, and study designs. Systemic administration can produce adverse effects such as dizziness, sedation, impaired coordination, tachycardia, and potential neurocognitive changes—factors that are clinically relevant for safety and adherence. Additionally, IOP reductions observed with cannabinoids may be modest, short-lived, and not yet established as sufficient or comparable to standard-of-care therapy for long-term neuroprotection.

A critical point is that glaucoma management requires sustained IOP control and ongoing monitoring. Any substance promoted as a “cure” risks delaying proven treatments such as drops, laser, or surgery. Neuroprotective strategies are an active research area, but as of current evidence, no cannabis product has demonstrated definitive disease-curing capability. Patients should not discontinue prescribed therapy or use cannabis in place of established treatment without ophthalmologist guidance.

Citrus-derived compounds, including lime (Citrus aurantiifolia) constituents, are often discussed in alternative health contexts. While vitamin C and various phytochemicals possess antioxidant properties in laboratory settings, there is no robust clinical evidence that lime consumption or topical lime preparations can cure glaucoma. Antioxidant effects observed in vitro do not reliably translate into meaningful optic nerve neuroprotection in vivo at safe, achievable concentrations. Moreover, ingesting citrus does not bypass the central therapeutic need: lowering IOP and monitoring progressive damage.

From an evidence-based perspective, the appropriate framing is “adjunctive research interest” rather than therapeutic replacement. If cannabis is considered for other indications, clinicians may discuss ocular implications and emphasize that any potential IOP effect does not negate the need for guideline-based glaucoma therapy. For lime or other citrus products, the focus should remain on general nutrition and overall eye health, not disease cure claims.

Safety considerations are also paramount. Patients with glaucoma are frequently older and may have comorbid cardiovascular or neurologic conditions. Systemic cannabinoids may interact with medications or exacerbate side effects. Topical or homemade eye applications—especially acidic substances—carry risk of ocular surface injury, corneal irritation, infection, or worsening inflammation. Therefore, only medically evaluated eye drops, and only as directed by eye-care professionals, should be considered.

In summary, glaucoma is a multifactorial optic neuropathy requiring early detection, individualized IOP targets, and sustained evidence-based treatment. Current medical literature supports IOP lowering as a key strategy to slow progression, while cannabinoids and citrus products remain investigational or unsupported as cures. Public health messaging should prioritize accurate risk communication, discourage unverified “cure” claims, and encourage adherence to established care pathways to preserve vision.

Source: @HerbalistChief